News for Aptevo Therapeutics Inc. (APVO)

Aptevo Therapeutics (APVO) experienced a trading halt with an announcement expected soon. Investors await the forthcoming news, which could potentially impact t

SEATTLE, WA / ACCESS Newswire / May 22, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a revers

Aptevo Therapeutics, under the ticker (APVO), will undergo a reverse stock split, consolidating its common shares in a 1-for-20 ratio. This adjustment is set to

Aptevo Therapeutics (APVO) announces a 1-for-20 reverse stock split effective May 23, 2025. The measure is part of a strategy to maintain Nasdaq Capital

9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trialsMipletamig triplet combination continues to outperform stan

Aptevo Therapeutics (APVO) is celebrating significant progress in its RAINIER trial, highlighting mipletamig as a promising candidate in the treatment of acute

Applied Materials (AMAT) to announce fiscal Q2 2025 earnings on May 15, 2025. Aptevo Therapeutics (APVO) participates in two major conferences in March

Evogene (EVGN), a computational biology company, is experiencing a notable 3,980% surge in investor attention, according to recent data. This surge coincides wi

SEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focu

Aptevo Therapeutics (APVO) closes $2.0 million registered direct offering. Offering price set at $0.862 per share, conducted under Nasdaq market rules.

Aptevo Therapeutics (APVO) raises $2.1 million through a successful share offering. Future growth potential highlighted by an ambitious analyst price ta

Shares of Netflix, Inc. NFLX rose sharply in today's pre-market trading following first-quarter results. Netflix reported stronger-than-expected first-quarter ...

SEATTLE, WASHINGTON / ACCESS Newswire / April 4, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology compa

SEATTLE, WA / ACCESS Newswire / April 3, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focus

Aptevo Therapeutics (APVO) announces a $2.1M funding through direct offering and private placement to support product development.

Washington-based Aptevo Therapeutics Inc. (APVO) is up over 129 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Washington-based Aptevo Therapeutics Inc. (APVO) is up over 129 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Shares of Penguin Solutions, Inc. PENG rose sharply in today's pre-market trading after the company posted better-than-expected results for its second quarter o...

Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of careTriplet Combination wi